BioSpace News Archive

Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, prior to the market open.

Agilent Technologies Inc. announced that CFO Bob McMahon will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference in Boston, Massachusetts, on Monday, March 4, at 2:50 p.m. EST.

REGENXBIO Inc. (Nasdaq: RGNX) today announced topline results from the Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II) demonstrating that the pivotal phase of the trial met its primary endpoint with statistical significance.

Cencora, Inc. announced the closing of its public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034, in an underwritten registered public offering.

Candela Corporation announced that it is partnering with Dr. Mariela Cogorno of Mariela Cogorno, MD as a new Candela Center of Excellence.

The U.K. health assessor the National Institute of Health and Care Excellence (NICE) has issued guidance endorsing the use of Brainomix 360 (formerly known as e-Stroke) to help clinical decision making in stroke.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2023 and business updates after market close on Thursday, February 15, 2024.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024, which ended December 31, 2023.

Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock.

QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”).